Jagsonpal Pharmaceuticals Limited , a trusted name in the Indian pharmaceutical industry, reported a flat quarterly performance for Q2, with revenue holding steady at Rs. 74.5 crores. The company faced challenges due to the GST transition but managed to maintain its EBITDA at Rs. 18.1 crores with a 24.3% margin. Despite these hurdles, Jagsonpal saw its Profit After Tax (PAT) grow by 10% to Rs. 12.6 crores.

H1 Performance

For the first half of the fiscal year, Jagsonpal demonstrated stronger results:

Leadership Expansion

In a move to strengthen its leadership team, Jagsonpal made two key appointments:

1. Amrut Medhekar as Chief Operating Officer

   • Brings 30 years of pharma experience
   • Previous roles at Wockhardt, Zydus, Ranbaxy, and Torrent

2. Nirav Vora as Chief Financial Officer

   • 18 years of finance experience

Market Challenges and GST Impact

The Indian pharmaceutical market grew by 7.5% in Q2, driven mainly by price increases and new product launches. However, Jagsonpal's therapy segments experienced slower growth of 2.5-3%.

The introduction of GST 2.0 reforms in September brought both opportunities and challenges:

• Reduction in GST rates from 12-18% to 5% for the pharmaceutical sector
• Temporary challenges in September due to inventory adjustments
• Company offered extra 30-day credit or 1% additional discount to channel partners

Financial Position

Despite paying out dividends of Rs. 16.7 crores, Jagsonpal maintained a strong cash position of Rs. 160.4 crores.

Future Outlook

Management expects a stronger performance in the second half of the fiscal year, targeting low double-digit growth. The company aims to:

• Deepen market penetration
• Expand core therapy areas
• Drive science-led innovation
• Strengthen leadership in women's health and related segments

Earnings Call Highlights

During the Q2 earnings call, management provided additional insights:

• The company maintains its 8th position in corporate CVM ranking
• Focus on upskilling Medical Representatives (MRs) for scientific engagement and enhanced productivity
• Continued investment in CSR initiatives to reinforce trust and quality

Jagsonpal Pharmaceuticals continues to navigate market challenges while focusing on growth and operational efficiency. With its expanded leadership team and strategic focus on key therapeutic areas, the company is positioning itself for stronger performance in the coming quarters.

Jagsonpal Pharmaceuticals Limited , a key player in the Indian pharmaceutical sector, has announced its unaudited financial results for the quarter and half year ended September 30, 2025, showcasing a mixed performance.

Financial Highlights

Jagsonpal Pharmaceuticals reported a net profit of 125.74 million rupees for the quarter, marking a 9.73% increase from 114.59 million rupees in the same period last year. This growth in profitability comes despite a marginal 0.30% year-over-year decline in revenue, which stood at 744.65 million rupees compared to 746.92 million rupees in the corresponding quarter of the previous fiscal year.

Operational Performance

The company's EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) showed improvement, rising to 165.00 million rupees from 162.00 million rupees in the year-ago period. This resulted in an EBITDA margin expansion of 46 basis points, reaching 22.15% compared to 21.69% in the same quarter last year.

Corporate Actions

The company's Board of Directors approved these unaudited financial results at a meeting held on November 3, 2025. During the quarter, Jagsonpal Pharmaceuticals granted 272,500 stock options to eligible employees under its Employee Stock Option Plan 2022 and allotted 104,774 equity shares upon exercise of vested stock options.

Dividend Information

Jagsonpal Pharmaceuticals paid a final dividend of Rs. 2.5 per equity share (face value Rs. 2 each), totaling Rs. 166.58 million for the year ended March 31, 2025. This dividend was approved by shareholders at the Annual General Meeting held on September 24, 2025.

Business Overview

The company primarily operates in manufacturing and trading of pharmaceutical products, including active pharmaceutical ingredients, for customers in India and overseas.

Audit Review

The financial results were reviewed by the Audit Committee, and a limited review was conducted by statutory auditors Walker Chandiok & Co LLP.

The company's ability to maintain profitability and improve margins in a challenging revenue environment demonstrates resilience. However, the slight dip in revenue might warrant attention to the company's growth strategies in the coming quarters.